Table 3.
Comparisons between treatments (HR, 95% credibility interval) in endocrine-resistant patients, both for progression-free survival (column vs row) and overall survival (row vs column)
| Progression-free survival, HR (95% CrI) | |||||||||||||||||||||
| Treatment | Metformin +AI |
Anti-andro (single) | F250 | Lapatinib +F250 |
Goserelin | AI | F250 +AI |
Anti-andro +AI |
Lapatinib +AI |
Tucidinos-tat+AI | F500 | Vistus. cont +F500 |
Vistus. int +F500 |
Bortezo-mib +F500 |
Pan-PI3Ki +F500 |
Everolim-us+AI | MultiTKI +F500 |
Everolim-us+F500 | Capivaser -tib +F500 |
CDK4/6i +F500 |
|
| Overall survival, HR (95% CrI) | Metformin +AI |
0.92 (0.49–1.75) |
0.88 (0.48–1.61) |
0.88 (0.46–1.31) |
0.85 (0.42–1.71) |
0.83 (0.48–1.44) |
0.84 (0.46–1.53) |
0.81 (0.45–1.50) |
0.65 (0.35–1.22) |
0.63 (0.34–1.15) |
0.52 (0.25–1.07) |
0.45 (0.21–0.98) |
0.40 (0.18–0.88) |
0.38 (0.16–0.86) |
0.38 (0.19–0.81) |
0.37 (0.21–0.67) |
0.35 (0.14–0.86) |
0.32 (0.15–0.69) |
0.30 (0.13–0.68) |
0.27 (0.13–0.57) |
|
| Anti-andro (single) | – | 0.96 (0.64–1.43) |
0.96 (0.59–1.54) |
0.91 (0.53–1.57) |
0.90 (0.66–1.24) |
0.90 (0.60–1.36) |
0.88 (0.64–1.21) |
0.70 (0.45–1.10) |
0.67 (0.45–1.02) |
0.56 (0.31–0.98) |
0.49 (0.25–0.93) |
0.43 (0.22–0.83) |
0.41 (0.20–0.82) |
0.42 (0.23–0.75) |
0.41 (0.28–0.58) |
0.38 (0.18–0.81) |
0.35 (0.18–0.66) |
0.32 (0.16–0.64) |
0.29 (0.16–0.53) |
||
| F250 | 1.15 (0.50–2.62) |
– | 1.00 (0.76–1.31) |
0.96 (0.58–1.58) |
0.94 (0.74–1.20) |
0.95 (0.74–1.21) |
0.92 (0.65–1.31) |
0.74 (0.50–1.09) |
0.71 (0.50–1.01) |
0.59 (0.34–1.00) |
0.51 (0.28–0.94) |
0.45 (0.24–0.84) |
0.43 (0.22–0.83) |
0.44 (0.25–0.75) |
0.42 (0.32–0.57) |
0.40 (0.19–0.83) |
0.36 (0.20–0.66) |
0.34 (0.18–0.65) |
0.31 (0.18–0.53) |
||
| Lapatinib +F250 |
– | – | – | 0.96 (0.54–1.69) |
0.94 (0.66–1.35) |
0.95 (0.66–1.35) |
0.92 (0.59–1.44) |
0.74 (0.46–1.19) |
0.71 (0.45–1.10) |
0.58 (0.32–1.06) |
0.51 (0.26–0.99) |
0.45 (0.23–0.89) |
0.43 (0.21–0.88) |
0.44 (0.24–0.80) |
0.42 (0.28–0.63) |
0.40 (0.18–0.87) |
0.36 (0.19–0.70) |
0.34 (0.17–0.69) |
0.31 (0.17–0.56) |
||
| Goserelin | 1.76 (0.56–5.55) |
– | 1.53 (0.64–3.67) |
– | 0.98 (0.63–1.53) |
0.99 (0.60–1.64) |
0.96 (0.58–1.60) |
0.77 (0.45–1.32) |
0.74 (0.44–1.23) |
0.61 (0.37–1.00) |
0.53 (0.30–0.95) |
0.47 (0.26–0.85) |
0.45 (0.24–0.85) |
0.46 (0.27–0.76) |
0.44 (0.28–0.71) |
0.42 (0.20–0.85) |
0.38 (0.21–0.67) |
0.35 (0.19–0.66) |
0.32 (0.19–0.53) |
||
| AI | 0.91 (0.42–1.99) |
– | 0.79 (0.60–1.05) |
– | 0.52 (0.22–1.18) |
1.01 (0.78–1.29) |
0.98 (0.76–1.27) |
0.78 (0.57–1.07) |
0.75 (0.58–0.97) |
0.62 (0.39–0.99) |
0.54 (0.31–0.95) |
0.48 (0.27–0.85) |
0.45 (0.24–0.84) |
0.46 (0.28–0.75) |
0.45 (0.38–0.54) |
0.42 (0.21–0.85) |
0.38 (0.22–0.67) |
0.36 (0.20–0.66) |
0.33 (0.20–0.53) |
||
| F250 +AI |
0.97 (0.42–2.23) |
– | 0.85 (0.64–1.13) |
– | 0.56 (0.23–1.33) |
1.07 (0.80–1.42) |
0.97 (0.68–1.40) |
0.78 (0.52–1.16) |
0.75 (0.52–1.07) |
0.62 (0.36–1.05) |
0.54 (0.29–0.99) |
0.48 (0.26–0.89) |
0.45 (0.23–0.88) |
0.46 (0.27–0.80) |
0.45 (0.33–0.61) |
0.42 (0.20–0.88) |
0.38 (0.21–0.70) |
0.36 (0.19–0.69) |
0.32 (0.19–0.56) |
||
| Anti-andro +AI |
– | – | – | – | – | – | – | 0.80 (0.53–1.19) |
0.77 (0.53–1.11) |
0.63 (0.37–1.08) |
0.55 (0.30–1.02) |
0.49 (0.26–0.91) |
0.46 (0.24–0.90) |
0.47 (0.27–0.82) |
0.46 (0.34–0.63) |
0.43 (0.21–0.91) |
0.39 (0.21–0.72) |
0.37 (0.19–0.71) |
0.33 (0.19–0.58) |
||
| Lapatinib +AI |
– | – | – | – | – | – | – | – | 0.96 (0.64–1.44) |
0.79 (0.45–1.41) |
0.69 (0.36–1.32) |
0.61 (0.32–1.18) |
0.58 (0.29–1.17) |
0.59 (0.33–1.06) |
0.58 (0.40–0.83) |
0.54 (0.25–1.17) |
0.49 (0.26–0.93) |
0.46 (0.23–0.91) |
0.42 (0.23–0.75) |
||
| Tucidinos-tat +AI |
– | – | – | – | – | – | – | – | – | 0.83 (0.48–1.42) |
0.72 (0.39–1.35) |
0.64 (0.34–1.20) |
0.60 (0.31–1.19) |
0.62 (0.35–1.08) |
0.60 (0.44–0.83) |
0.56 (0.27–1.19) |
0.51 (0.28–0.95) |
0.48 (0.25–0.93) |
0.43 (0.25–0.76) |
||
| F500 | 1.06 (0.34–3.27) |
– | 0.92 (0.39–2.18) |
– | 0.60 (0.28–1.33) |
1.16 (0.52–2.61) |
1.09 (0.46–2.60) |
– | – | – | 0.87 (0.65–1.18) |
0.77 (0.56–1.06) |
0.73 (0.49–1.09) |
0.75 (0.67–0.84) |
0.73 (0.44–1.20) |
0.68 (0.41–1.13) |
0.62 (0.47–0.82) |
0.58 (0.40–0.85) |
0.52 (0.46–0.60) |
||
| Vistus. cont+F500 | – | – | – | – | – | – | – | – | – | – | – | 0.89 (0.69–1.14) |
0.84 (0.51–1.38) |
0.86 (0.62–1.18) |
0.83 (0.46–1.50) |
0.78 (0.43–1.41) |
0.71 (0.54–0.94) |
0.66 (0.41–1.08) |
0.60 (0.43–0.84) |
||
| Vistus. int +F500 |
– | – | – | – | – | – | – | – | – | – | – | – | 0.95 (0.57–1.58) |
0.97 (0.69–1.36) |
0.94 (0.52–1.71) |
0.88 (0.48–1.61) |
0.80 (0.60–1.08) |
0.75 (0.46–1.24) |
0.68 (0.48–0.96) |
||
| Bortezomib +F500 |
– | – | – | – | – | – | – | – | – | – | – | – | – | 1.02 (0.67–1.55) |
0.99 (0.52–1.90) |
0.93 (0.49–1.78) |
0.85 (0.52–1.38) |
0.79 (0.45–1.38) |
0.72 (0.47–1.10) |
||
| Pan-PI3Ki+F500 | 0.92 (0.29–2.86) |
– | 0.80 (0.33–1.92) |
– | 0.52 (0.24–1.17) |
1.01 (0.44–2.32) |
0.95 (0.39–2.28) |
– | – | – | 0.87 (0.74–1.02) |
– | – | – | 0.97 (0.58–1.63) |
0.91 (0.54–1.53) |
0.83 (0.61–1.13) |
0.78 (0.52–1.16) |
0.70 (0.59–0.84) |
||
| Everolimus +AI |
0.81 (0.36–1.83) |
– | 0.71 (0.50–1.00) |
– | 0.46 (0.20–1.08) |
0.89 (0.73–1.09) |
0.83 (0.58–1.18) |
– | – | – | 0.76 (0.33–1.77) |
– | – | – | 0.88 (0.38–2.08) |
0.94 (0.46–1.92) |
0.85 (0.48–1.52) |
0.80 (0.42–1.50) |
0.72 (0.43–1.22) |
||
| MultiTKI+F500 | 0.86 (0.22–3.27) |
– | 0.75 (0.24–2.28) |
– | 0.49 (0.17–1.40) |
0.94 (0.32–2.78) |
0.88 (0.28–2.71) |
– | – | – | 0.81 (0.39–1.67) |
– | – | – | 0.93 (0.44–1.94) |
1.06 (0.35–3.20) |
0.91 (0.51–1.64) |
0.85 (0.45–1.61) |
0.77 (0.46–1.31) |
||
| Everolimus +F500 |
1.38 (0.38–5.00) |
– | 1.21 (0.42–3.45) |
– | 0.79 (0.29–2.13) |
1.52 (0.56–4.20) |
1.43 (0.50–4.09) |
– | – | – | 1.31 (0.72–2.39) |
– | – | – | 1.51 (0.81–2.82) |
1.71 (0.61–4.83) |
1.61 (0.64–4.12) |
0.93 (0.58–1.50) |
0.85 (0.62–1.16) |
||
| Capivaser-tib+F500 | 0.63 (0.18–2.20) |
– | 0.54 (0.20–1.53) |
– |
0.35 (0.13–0.93) |
0.69 (0.26–1.85) |
0.64 (0.23–1.81) |
– | – | – | 0.59 (0.34–1.04) |
– | – | – | 0.68 (0.38–1.22) |
0.77 (0.28–2.13) |
0.73 (0.29–1.83) |
0.45 (0.20–1.02) |
0.91 (0.60–1.36) |
||
| CDK4/6i +F500 |
0.82 (0.26–2.54) |
– | 0.71 (0.30–1.71) |
– | 0.46 (0.21–1.03) |
0.90 (0.39–2.05) |
0.84 (0.35–2.02) |
– | – | – |
0.77 (0.67–0.89) |
– | – | – | 0.89 (0.71–1.10) |
1.01 (0.43–2.35) |
0.95 (0.46–1.99) |
0.59 (0.32–1.08) |
1.31 (0.73–2.33) |
||
Treatments in the cells closer to the right-upper corner of the table are usually better than treatments in the cells closer to the upper-left corner. Cells in bold: statistically significant difference.
*±goserelin.
AI, aromatase inhibitor; anti-andro, anti-androgen agent; CDK, cyclin-dependent kinase; CDK4/6i, CDK4/6 inhibitor; cont, continuous; F250, fulvestrant 250 mg; F500, fulvestrant 500 mg; int, intermittent; multiTKI, multi-tyrosine kinase inhibitor; pan-PI3Ki, pan-PI3K inhibitor; vistus., vistusertib.